



Please affix a plus sign (+) in this box ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
PTO/SB (12-97)  
0348 0651-0001

Use/Submit form 1449/PTO

**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/616,649
Filing Date	07/09/03
First Named Inventor	Chiao
Group Art Unit / Conf. No.	1614 / 9975
Examiner Name	Not Yet Assigned
Attorney Docket Number	24852-501 CIP2

**U.S. PATENT DOCUMENTS**

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
MG	A25*	4,690,918	09/01/87	Beppu, et al.			
	A26*	5,654,333	08/05/97	The United States of America as represented by the Department of Health and Human Services			
	A27*	6,239,176	05/29/01	Beacon Laboratories, Inc. et al.			
	A28*	6,262,116	07/17/01	Sloan-Kettering Institute for Cancer Research			
	A29*	6,451,334	09/17/02	Perrine			
	A30*	6,495,719	12/17/02	CircaGen Pharmaceuticals			
	A31*	2003/0114525	06/19/03	Kammer, et al.			
	A32*	2004/0132643	07/08/04	Fojo, et al.			
	A33*	2004/0167184	08/26/04	Wiech, et al.			
MG	A34	6,495,719	12/17/02	Lan-Harpest, et al.			

**FOREIGN PATENT DOCUMENTS**

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	English Yes No
MG	B14*	WO 98/39965	Beacon Laboratories, LLC	09/17/98	X
	B15*	WO 02/15921	The Government of the United States of America	02/28/02	X
MG	B16*	WO 02/055017	Wake Forest University	07/18/02	X

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
MG	C83*	"Aton Pharma, Inc. Announces Initiation of Two Phase II Trials to Evaluate Efficacy of HDAC Inhibitor SAHA", October 30, 2002.
	C84*	"Aton Pharma, Inc. Announces Phase I Clinical Trial of SAHA in Advanced Leukemias", July 1, 2003.
	C85*	"Aton Pharma, Inc. Appoints Judy H. Chiao, M.D., as Vice President, Oncology Clinical Research and Development", September 20, 2002.
	C86*	"Aton Pharma, Inc. Presents Phase I Trial Data of Anti-Cancer Agent SAHA in Patients with hematological Malignancy at ASCO", June 2, 2003.
	C87*	"Aton Pharma, Inc. Presents Phase I Trial Data on Anti-Cancer Agent SAHA at EORTC/NCI/AACR Symposium", November 21, 2002.
MG	C88*	"Aton Pharma, Inc. Received Orphan Drug Designation for SAHA in Multiple Myeloma and Initiates Phase I